Outsourcing

Articles

The investment at its Madison, WI, facility will expand MilliporeSigma’s capacity for high-potent active pharmaceutical ingredient production and allow for continuous flow manufacturing of ADCs.

MilliporeSigma Invests $65 Million to Expand Antibody-Drug Conjugate Manufacturing

The company is investing $130 million to add Phase III through commercial-scale manufacturing suites to its gene therapy campus in Harmans, MD.

Catalent Invests $130 Million to Expand Gene Therapy Manufacturing Capacity

Jennifer Markarian is manufacturing editor of Pharmaceutical Technology.

Rapid scale-up to billions of doses requires collaborative, all-out efforts by innovators, their manufacturing partners, and the entire supply chain. 

Preparing Pandemic Vaccine Capacity

Ronald A. Rader is senior director, Technical Research, at BioPlan Associates.

Cellular and gene therapy fields are currently on track for, if not already experiencing, a serious capacity crunch. 

Cellular and Gene Therapies Face a Manufacturing Capacity Crunch

CDMO Avid Bioservices will provide development and drug substance manufacturing for Oragenics’ novel COVID-19 vaccine candidate, Terra CoV-2. 

Oragenics and Avid Bioservices Collaborate on Coronavirus Vaccine

The company has made several moves in recent weeks to expand manufacturing capacity and cell line services.

Samsung Biologics Expands Manufacturing Facilities and Launches Cell Line Technology

Fujifilm Diosynth Biotechnologies’ North Carolina site will be used to manufacture Novavax’ NVX‑CoV2373 vaccine candidate for a Phase III clinical trial. 

Novavax and Fujifilm Diosynth Biotechnologies Begin Manufacturing of COVID-19 Vaccine Candidate

Catalent has unveiled investment plans to create a European center of excellence for clinical biologics formulation development and drug product fill/finish services.

Catalent Invests Millions to Create European Clinical Manufacturing Center of Excellence

Catalent has unveiled plans to invest in a European center of excellence for clinical biologics formulation development and drug product fill/finish services at its facility in Limoges, France.

Susan Haigney is managing editor of BioPharm International, susan.haigney@ubm.com.

The COVID-19 pandemic has created a rise in demand for R&D and a shift in focus for some contract organizations.

Contract Manufacturing, Biopharmaceutical Production